Business
Natera Provides Remote Access to Tests Without Requiring Live Office Visits
Enabling continuity of care while allowing patients to stay home SAN CARLOS, Calif., March 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and
About this update from Natera, Inc.
[{"type":"text","content":"Enabling continuity of care while allowing patients to stay home\n\n\nSAN CARLOS, Calif., March 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities across its reproductive, oncology and organ transplant businesses.\n\n \n \n \n \n \n \n\n \nNatera's tests inform critical medical decisions, and the need to carry out these essential tests does not stop, even in these challenging times. To meet this demand, testing can be fulfilled remotely, delivered at the push of a button with virtual ordering and remote blood draws in the comfort and safety of a patient's home. \"We are focused on helping physicians ensure continuity of essential medical care, while protecting the safety and well-being of our patients,\" said Steve Chapman, CEO.\nThe remote functionality is fulfilled through Natera's online platforms and a nationwide mobile blood draw network that performed roughly 10,000 in-home draws in 2019. \nNatera provides essential medical services for thousands of patients every day, and our laboratories continue to operate at high throughput levels. Stringent health and safety precautions have been implemented in all of our facilities to ensure the continuity of testing operations. These include daily health checks for lab staff and a work-from-home policy for all non-lab employees.\nAbout Natera Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.\nForward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be ach...